Related Articles
A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report
ALK inhibitors and advanced non-small cell lung cancer (Review)
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study